Endometrial Cancer – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Endometrial Cancer – Pipeline Review, H2 2016’, provides an overview of the Endometrial Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Endometrial Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Endometrial Cancer

The report reviews pipeline therapeutics for Endometrial Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Endometrial Cancer therapeutics and enlists all their major and minor projects

The report assesses Endometrial Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Endometrial Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Endometrial Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Endometrial Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ability Pharmaceuticals, S.L.

Advenchen Laboratories, LLC

Aeterna Zentaris Inc.

ArQule, Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

BeiGene, Ltd.

BioNTech AG

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Cellceutix Corporation

Critical Outcome Technologies Inc

Eisai Co., Ltd.

Eli Lilly and Company

Esperance Pharmaceuticals, Inc.

Exelixis, Inc.

F. Hoffmann-La Roche Ltd.

Galena Biopharma, Inc.

GamaMabs Pharma S.A.

Genmab A/S

GlaxoSmithKline Plc

Gradalis Inc.

Horizon Pharma Plc

Immunocore Ltd

ImmunoGen, Inc.

Incyte Corporation

Innate Pharma S.A.

Karyopharm Therapeutics, Inc.

Merck & Co., Inc.

Merck KGaA

Millennium Pharmaceuticals Inc

Novartis AG

OncoHoldings, Inc.

Ono Pharmaceutical Co., Ltd.

Pfizer Inc.

Pharma Mar, S.A.

Pharmsynthez

Pivot Pharmaceuticals Inc

Puma Biotechnology, Inc.

Sanofi

Shenogen Pharma Group Ltd

Sigma-Tau S.p.A.

Synthon Holdings BV

Vertex Pharmaceuticals Incorporated

Vyriad Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Endometrial Cancer Overview 7

Therapeutics Development 8

Endometrial Cancer - Therapeutics under Development by Companies 10

Endometrial Cancer - Therapeutics under Investigation by Universities/Institutes 13

Endometrial Cancer - Pipeline Products Glance 14

Endometrial Cancer - Products under Development by Companies 17

Endometrial Cancer - Products under Investigation by Universities/Institutes 21

Endometrial Cancer - Companies Involved in Therapeutics Development 22

Endometrial Cancer - Therapeutics Assessment 67

Drug Profiles 83

Endometrial Cancer - Dormant Projects 384

Endometrial Cancer - Discontinued Products 387

Endometrial Cancer - Product Development Milestones 388

Appendix 403

List of Tables

List of Tables

Number of Products under Development for Endometrial Cancer, H2 2016 16

Number of Products under Development for Endometrial Cancer – Comparative Analysis, H2 2016 17

Number of Products under Development by Companies, H2 2016 18

Number of Products under Development by Companies, H2 2016 (Contd..1) 19

Number of Products under Development by Companies, H2 2016 (Contd..2) 20

Number of Products under Investigation by Universities/Institutes, H2 2016 21

Comparative Analysis by Late Stage Development, H2 2016 22

Comparative Analysis by Clinical Stage Development, H2 2016 23

Comparative Analysis by Early Stage Development, H2 2016 24

Products under Development by Companies, H2 2016 25

Products under Development by Companies, H2 2016 (Contd..1) 26

Products under Development by Companies, H2 2016 (Contd..2) 27

Products under Development by Companies, H2 2016 (Contd..3) 28

Products under Investigation by Universities/Institutes, H2 2016 29

Endometrial Cancer – Pipeline by Ability Pharmaceuticals, S.L., H2 2016 30

Endometrial Cancer – Pipeline by Advenchen Laboratories, LLC, H2 2016 31

Endometrial Cancer – Pipeline by Aeterna Zentaris Inc., H2 2016 32

Endometrial Cancer – Pipeline by ArQule, Inc., H2 2016 33

Endometrial Cancer – Pipeline by AstraZeneca Plc, H2 2016 34

Endometrial Cancer – Pipeline by AVEO Pharmaceuticals, Inc., H2 2016 35

Endometrial Cancer – Pipeline by BeiGene, Ltd., H2 2016 36

Endometrial Cancer – Pipeline by BioNTech AG, H2 2016 37

Endometrial Cancer – Pipeline by Boehringer Ingelheim GmbH, H2 2016 38

Endometrial Cancer – Pipeline by Bristol-Myers Squibb Company, H2 2016 39

Endometrial Cancer – Pipeline by Cellceutix Corporation, H2 2016 40

Endometrial Cancer – Pipeline by Critical Outcome Technologies Inc, H2 2016 41

Endometrial Cancer – Pipeline by Eisai Co., Ltd., H2 2016 42

Endometrial Cancer – Pipeline by Eli Lilly and Company, H2 2016 43

Endometrial Cancer – Pipeline by Esperance Pharmaceuticals, Inc., H2 2016 44

Endometrial Cancer – Pipeline by Exelixis, Inc., H2 2016 45

Endometrial Cancer – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 46

Endometrial Cancer – Pipeline by Galena Biopharma, Inc., H2 2016 47

Endometrial Cancer – Pipeline by GamaMabs Pharma S.A., H2 2016 48

Endometrial Cancer – Pipeline by Genmab A/S, H2 2016 49

Endometrial Cancer – Pipeline by GlaxoSmithKline Plc, H2 2016 50

Endometrial Cancer – Pipeline by Gradalis Inc., H2 2016 51

Endometrial Cancer – Pipeline by Horizon Pharma Plc, H2 2016 52

Endometrial Cancer – Pipeline by Immunocore Ltd, H2 2016 53

Endometrial Cancer – Pipeline by ImmunoGen, Inc., H2 2016 54

Endometrial Cancer – Pipeline by Incyte Corporation, H2 2016 55

Endometrial Cancer – Pipeline by Innate Pharma S.A., H2 2016 56

Endometrial Cancer – Pipeline by Karyopharm Therapeutics, Inc., H2 2016 57

Endometrial Cancer – Pipeline by Merck & Co., Inc., H2 2016 58

Endometrial Cancer – Pipeline by Merck KGaA, H2 2016 59

Endometrial Cancer – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 60

Endometrial Cancer – Pipeline by Novartis AG, H2 2016 61

Endometrial Cancer – Pipeline by OncoHoldings, Inc., H2 2016 62

Endometrial Cancer – Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 63

Endometrial Cancer – Pipeline by Pfizer Inc., H2 2016 64

Endometrial Cancer – Pipeline by Pharma Mar, S.A., H2 2016 65

Endometrial Cancer – Pipeline by Pharmsynthez, H2 2016 66

Endometrial Cancer – Pipeline by Pivot Pharmaceuticals Inc, H2 2016 67

Endometrial Cancer – Pipeline by Puma Biotechnology, Inc., H2 2016 68

Endometrial Cancer – Pipeline by Sanofi, H2 2016 69

Endometrial Cancer – Pipeline by Shenogen Pharma Group Ltd, H2 2016 70

Endometrial Cancer – Pipeline by Sigma-Tau S.p.A., H2 2016 71

Endometrial Cancer – Pipeline by Synthon Holdings BV, H2 2016 72

Endometrial Cancer – Pipeline by Vertex Pharmaceuticals Incorporated, H2 2016 73

Endometrial Cancer – Pipeline by Vyriad Inc, H2 2016 74

Assessment by Monotherapy Products, H2 2016 75

Assessment by Combination Products, H2 2016 76

Number of Products by Stage and Target, H2 2016 78

Number of Products by Stage and Mechanism of Action, H2 2016 83

Number of Products by Stage and Route of Administration, H2 2016 88

Number of Products by Stage and Molecule Type, H2 2016 90

Endometrial Cancer – Dormant Projects, H2 2016 392

Endometrial Cancer – Dormant Projects (Contd..1), H2 2016 393

Endometrial Cancer – Dormant Projects (Contd..2), H2 2016 394

Endometrial Cancer – Discontinued Products, H2 2016 395

List of Figures

List of Figures

Number of Products under Development for Endometrial Cancer, H2 2016 16

Number of Products under Development for Endometrial Cancer – Comparative Analysis, H2 2016 17

Number of Products under Development by Companies, H2 2016 18

Number of Products under Investigation by Universities/Institutes, H2 2016 21

Comparative Analysis by Clinical Stage Development, H2 2016 23

Comparative Analysis by Early Stage Products, H2 2016 24

Assessment by Monotherapy Products, H2 2016 75

Assessment by Combination Products, H2 2016 76

Number of Products by Top 10 Targets, H2 2016 77

Number of Products by Stage and Top 10 Targets, H2 2016 77

Number of Products by Top 10 Mechanism of Actions, H2 2016 82

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 82

Number of Products by Top 10 Routes of Administration, H2 2016 87

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 87

Number of Products by Top 10 Molecule Types, H2 2016 89

Number of Products by Stage and Top 10 Molecule Types, H2 2016 89

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports